A team of scientists from the Indiana University School of Medicine has discovered a new link between an age-related blood condition and inflammatory bowel disease, often called IBD.
Their research suggests that a process happening in the blood as people grow older may make gut inflammation worse.
The study also points to a possible new treatment approach that could reduce this inflammation without weakening the immune system.
Inflammatory bowel disease is a long-term condition that causes swelling and irritation in the digestive tract. The two main types are Crohn’s disease and ulcerative colitis.
People with these conditions often suffer from symptoms such as stomach pain, diarrhea, fatigue, weight loss, and frequent trips to the bathroom. In severe cases, the disease can damage the lining of the intestines and greatly reduce a person’s quality of life.
Doctors still do not fully understand why IBD develops. Many researchers believe it results from a mix of genetic factors, immune system problems, and environmental triggers. In recent years, scientists have also started looking at how aging may influence the disease.
Older adults are more likely to develop certain health problems related to chronic inflammation, and this new research suggests that changes in blood cells may play a role.
The study focused on a condition called clonal hematopoiesis of indeterminate potential, often shortened to CHIP. This condition happens when blood stem cells develop genetic mutations as people age.
Blood stem cells are special cells in the bone marrow that produce all the different types of blood cells the body needs. As people grow older, these cells can sometimes acquire small genetic changes. When a mutated stem cell begins to produce many identical blood cells, scientists call this clonal hematopoiesis.
CHIP is fairly common among older adults. Many people who have it never notice any symptoms. However, previous studies have shown that it is linked to a higher risk of certain health problems, including blood cancers, heart disease, and kidney disease.
Researchers have suspected that these mutated blood cells might increase inflammation in the body, but the connection to intestinal diseases had not been clearly demonstrated before.
The new research, published in the scientific journal Blood, provides strong evidence that CHIP may worsen inflammation in the digestive system.
The scientists analyzed large sets of health data from the UK Biobank and the National Institutes of Health’s All of Us Research Program. These databases contain genetic and medical information from hundreds of thousands of volunteers.
When the researchers examined the data, they found that people with CHIP had a higher risk of developing Crohn’s disease. The risk was particularly noticeable in women and in individuals whose blood cells carried mutations in a gene called DNMT3A.
The team also discovered that younger people with large mutations in another gene, called TET2, had a greater risk of developing ulcerative colitis.
To better understand what was happening inside the body, the scientists carried out experiments using mouse models. They observed that animals with CHIP-related mutations in their blood stem cells developed much more severe inflammation in the colon.
The mutated blood cells caused large numbers of immune cells to gather in the intestinal tissue, which led to more damage and swelling.
During these experiments, the researchers identified a specific biological pathway that appeared to drive the inflammation. This pathway involves a protein system known as APE1/Ref-1. The scientists discovered that when this pathway became highly active, it made the immune response in the gut much stronger than normal.
The research team then tested a drug called APX3330, which blocks this pathway. The drug was originally developed by Indiana University scientist Dr. Mark Kelley and has already been studied for safety in humans.
When the researchers gave this medication to their experimental models, they saw a dramatic improvement. Inflammation in the colon was reduced, tissue damage decreased, and the immune system began behaving more normally again.
According to the scientists, one of the most surprising results was how effectively the drug reversed the harmful effects linked to CHIP mutations. This finding suggests that even though CHIP is related to aging and genetic changes in blood cells, the damaging inflammation it causes may still be treatable.
This discovery could be important because many current treatments for inflammatory bowel disease suppress the immune system.
While these drugs can help control symptoms, they may also increase the risk of infections and other complications. A treatment that reduces inflammation without weakening the immune system could provide a safer option for many patients.
The research team is now preparing for an early-stage clinical trial to test the drug in people with IBD. This type of trial, known as a Phase Ib study, will help determine how well the drug works in patients and whether it continues to be safe.
The scientists also believe that the same strategy might help treat other diseases linked to chronic inflammation. Because CHIP has already been connected to heart disease, kidney problems, and other conditions associated with aging, targeting the APE1/Ref-1 pathway might have benefits beyond intestinal disorders.
Overall, this study offers an important new perspective on how aging, blood biology, and inflammation may be connected. By showing that mutated blood stem cells can intensify gut inflammation, the researchers have identified a new factor that may influence the development and severity of inflammatory bowel disease.
However, it is important to interpret these results carefully. Much of the experimental work was done in animal models, and human clinical trials are still needed to confirm whether the treatment works as well in patients.
The large population databases used in the study provide strong evidence of an association between CHIP and IBD risk, but they do not prove that the mutations directly cause the disease in every case.
Even with these limitations, the findings are promising. They suggest that age-related changes in blood cells may play a larger role in chronic inflammatory diseases than scientists previously realized.
If future clinical trials confirm these results, targeting the APE1/Ref-1 pathway could open the door to a new class of treatments for Crohn’s disease, ulcerative colitis, and possibly other inflammation-related conditions.
If you care about gut health, please read studies about how probiotics can protect gut health ,and Mycoprotein in diet may reduce risk of bowel cancer and improve gut health.
For more health information, please see recent studies about how food additives could affect gut health, and the best foods for gut health.
Copyright © 2026 Knowridge Science Report. All rights reserved.
